BRPI0813516A2 - Tratamento de distúrbios proliferativos de células b - Google Patents

Tratamento de distúrbios proliferativos de células b

Info

Publication number
BRPI0813516A2
BRPI0813516A2 BRPI0813516-9A2A BRPI0813516A BRPI0813516A2 BR PI0813516 A2 BRPI0813516 A2 BR PI0813516A2 BR PI0813516 A BRPI0813516 A BR PI0813516A BR PI0813516 A2 BRPI0813516 A2 BR PI0813516A2
Authority
BR
Brazil
Prior art keywords
proliferative
treatment
cell disorders
disorders
cell
Prior art date
Application number
BRPI0813516-9A2A
Other languages
English (en)
Inventor
Richard Rickles
Margaret S Lee
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0813516A2 publication Critical patent/BRPI0813516A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0813516-9A2A 2007-07-17 2008-07-17 Tratamento de distúrbios proliferativos de células b BRPI0813516A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95030707P 2007-07-17 2007-07-17
US96558707P 2007-08-21 2007-08-21
PCT/US2008/008758 WO2009011893A2 (en) 2007-07-17 2008-07-17 Treatments of b-cell proliferative disorders

Publications (1)

Publication Number Publication Date
BRPI0813516A2 true BRPI0813516A2 (pt) 2014-12-30

Family

ID=40260271

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813516-9A2A BRPI0813516A2 (pt) 2007-07-17 2008-07-17 Tratamento de distúrbios proliferativos de células b

Country Status (8)

Country Link
US (1) US20090053168A1 (pt)
EP (1) EP2178369A4 (pt)
AU (1) AU2008276451A1 (pt)
BR (1) BRPI0813516A2 (pt)
CA (1) CA2694983A1 (pt)
EA (1) EA201000219A1 (pt)
TW (1) TW200920381A (pt)
WO (1) WO2009011893A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200914048A (en) * 2007-07-17 2009-04-01 Combinatorx Inc Combinations for the treatment of B-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
KR20110028531A (ko) 2008-07-03 2011-03-18 유니버시티 오브 버지니아 페이턴트 파운데이션 아파데노손의 단위 용량
PT2321012T (pt) 2008-08-20 2019-01-11 Solasia Pharma K K Compostos organoarsénicos e métodos para o tratamento de cancro
CN108059635B (zh) 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
PH12013500261A1 (en) * 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
WO2012029994A1 (en) * 2010-09-02 2012-03-08 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
WO2014142220A1 (ja) * 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US9314460B1 (en) * 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
CN105899486A (zh) * 2013-12-05 2016-08-24 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
PL408251A1 (pl) * 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
IL263744B2 (en) 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
WO2022150512A1 (en) * 2021-01-07 2022-07-14 The Regents Of The University Of California Modulation of cd46 cell surface marker in both androgen receptor-positive and negative cancer cells
WO2022150517A1 (en) * 2021-01-07 2022-07-14 The Regents Of The University Of California Modulation of cd46 cell surface expression and therapeutic use thereof
CN112939996B (zh) * 2021-02-01 2022-04-26 湖南文理学院 一种以n-氧化吡啶衍生物为识别基团的近红外荧光探针化合物及其制备和应用
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
WO2024215814A2 (en) * 2023-04-10 2024-10-17 Anand Rene Methods and pharmaceutical compositions for treating aging
CN117886779A (zh) * 2023-12-21 2024-04-16 徐州医科大学 一种具有手性羟基的哌嗪醇类化合物及其制备方法和医药用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5925682A (en) * 1995-11-20 1999-07-20 Immunotech Inc. Epinephrine as inhibitor of cancerous tumors
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
US6399649B1 (en) * 1998-09-24 2002-06-04 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US20030017150A1 (en) * 2001-03-14 2003-01-23 Torphy Theodore J. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20050238660A1 (en) * 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
EP1587512A2 (en) * 2003-01-14 2005-10-26 ALTANA Pharma AG Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
PL2298743T3 (pl) * 2003-06-26 2013-02-28 Novartis Ag Inhibitory kinaz P38 na bazie 5-członowych heterocykli
EP1687284B1 (en) * 2003-07-25 2008-10-29 Novartis AG p-38 KINASE INHIBITORS
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
CA2640087A1 (en) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
CA2644136A1 (en) * 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
TW200914048A (en) * 2007-07-17 2009-04-01 Combinatorx Inc Combinations for the treatment of B-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
EP2178369A4 (en) 2010-12-15
WO2009011893A2 (en) 2009-01-22
TW200920381A (en) 2009-05-16
WO2009011893A3 (en) 2009-03-19
AU2008276451A1 (en) 2009-01-22
CA2694983A1 (en) 2009-01-22
EP2178369A2 (en) 2010-04-28
US20090053168A1 (en) 2009-02-26
EA201000219A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
EP2178370A4 (en) COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISEASES
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
BRPI0914841A2 (pt) aparelho de massagem
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
BRPI0910854A2 (pt) métodos de tratamento
IL211985A0 (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
PL3476371T3 (pl) Urządzenie do leczenia gerd
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
BRPI0919748A2 (pt) dipositivo de tratamento
GB0703909D0 (en) Treatment of anxiety disorders
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
PL2427193T3 (pl) Zastosowanie inhibitorów pde7 do leczenia zaburzeń ruchu
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
EP3381471C0 (en) PAIN TREATMENT
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI1010516A2 (pt) Métodos de tratamento de edema relacionados à isquemia-reperfusão
HRP20160577T1 (hr) Liječenje osteoartritisa
PT3133396T (pt) Métodos de tratamento utilizando fármacos eliminadores de amoníaco
DK2310017T3 (da) Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired